Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Ying Lv

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6448-5930; OpenAlex author ID A5079686991, A5121383693. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 19

  1. STING Agonist-Modified Tumor Targeting Photosensitizer Remodels Cancer-Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer. Last author DOI 10.1002/advs.202520547↗
  2. A pH-responsive liposomal nanoplatform for reprogramming lactate metabolism and immunogenic activation in pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2026.124401↗
  3. Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms. Last author DOI 10.1016/j.tranon.2026.102821↗
  4. Oroxylin A Directly Targets SRC to Inhibit the PI3K/AKT Signaling Axis in Pancreatic Cancer: An Integrated Bioinformatics and Experimental Study. Last author DOI 10.3390/biom16050685↗
  5. Clinical characteristics of pancreatic cancer presenting with acute pancreatitis: a propensity-matched cohort study. Co-author DOI 10.1007/s00464-025-11654-z↗
  6. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.202305279↗
  7. High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial… Co-author DOI 10.1016/j.bios.2024.116411↗
  8. Cinchonine-induced cell death in pancreatic cancer cells by downregulating RRP15. First author DOI 10.1002/cbin.11987↗
  9. Protein tyrosine phosphatase nonreceptor type 2 exerts antimetastatic functions in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/mc.23554↗
  10. Lithium chloride induces apoptosis by activating endoplasmic reticulum stress in pancreatic cancer. Last author DOI 10.1016/j.tranon.2023.101792↗
  11. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Last author DOI 10.1038/s41467-023-40727-7↗
  12. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Co-author DOI 10.1038/s41388-022-02328-4↗
  13. Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis. Co-author DOI 10.1039/d2bm00770c↗
  14. Gastric metastasis from pancreatic cancer characterized by mucosal erosion: a case report and literature review. Last author DOI 10.1177/03000605211003759↗
  15. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
  16. PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation. Co-author DOI 10.3389/fcell.2021.745554↗
  17. Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.628346↗
  18. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway. Last author DOI 10.1016/j.pan.2015.04.001↗
  19. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. Co-author DOI 10.1016/j.intimp.2013.12.022↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoping Zou · 13 shared papers, 2014–2026 · strength 1.81
  2. Shu Zhang · 10 shared papers, 2021–2026 · strength 1.49
  3. Shanshan Shen · 9 shared papers, 2021–2025 · strength 1.30
  4. Jiajun Zhang · 3 shared papers, 2026 · strength 0.78
  5. Yixuan Zhang · 4 shared papers, 2021–2023 · strength 0.56
  6. Yixuan Zhang · 3 shared papers, 2022–2026 · strength 0.54
  7. Hao Wu · 3 shared papers, 2022–2023 · strength 0.42
  8. Hongzhen Li · 3 shared papers, 2021–2025 · strength 0.41
  9. Shuang Nie · 3 shared papers, 2021–2025 · strength 0.41
  10. Song Zhang · 2 shared papers, 2024–2025 · strength 0.39
  11. Yixuan Zhang · 2 shared papers, 2023–2024 · strength 0.34
  12. Jialun Wang · 1 shared paper, 2026 · strength 0.32
  13. Helmut Friess · 2 shared papers, 2021–2025 · strength 0.29
  14. Hui Wang · 2 shared papers, 2021–2023 · strength 0.28
  15. Yukun Li · 1 shared paper, 2026 · strength 0.27
  16. Chao Yan · 2 shared papers, 2022–2023 · strength 0.26
  17. Dongming Zhu · 2 shared papers, 2021–2023 · strength 0.25
  18. Siqi Zhou · 2 shared papers, 2021–2022 · strength 0.24
  19. Yin Zhang · 1 shared paper, 2026 · strength 0.24
  20. Yu Zhao · 1 shared paper, 2026 · strength 0.24
  21. Y. Zhang · 1 shared paper, 2026 · strength 0.23
  22. Xuetian Qian · 2 shared papers, 2021 · strength 0.22
  23. Bo Kong · 2 shared papers, 2021 · strength 0.22
  24. Zhixian Zhu · 1 shared paper, 2024 · strength 0.20
  25. Nan Xiang · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.